Your browser doesn't support javascript.
loading
Lactococcus lactis : a new strategy for vaccination
AJMB-Avicenna Journal of Medical Biotechnology. 2017; 9 (4): 163-168
in En | IMEMR | ID: emr-189556
Responsible library: EMRO
Needle free vaccines have a several advantages and very attractive way for vaccination. In a body, mucosal surfaces provide a universal entry portal for all the known and emerging infectious pathogenic microbes. Therefore, it seems, vaccination strategies need to be reorganized for vaccines that are hindering the entry capability of pathogenic microbes through mucosal surfaces. Lactic acid Bacteria [LAB] are widely used in the food industry and at the present, used as delivery vehicles for biological investigations. In this review, we summarized the Results of several studies which Lactococcus lactis [L. lactis] used as a live vector for vaccines. These bacteria are considered as promising candidates for heterologous expression of proteins and biotechnological usage. LAB are considered as promising candidates for heterologous expression of proteins and biotechnological usage. The results showed that these bacteria have an ability to deliver antigen to immune system. Therefore, developing mucosal live vaccines using lactic acid bacterium, L. lactis, as an antigen delivery vector, is an attractive alternative choice and a safer vaccination strategy against pathogens
Search on Google
Index: IMEMR Language: En Journal: Avicenna J. Med. Biotechnol. Year: 2017
Search on Google
Index: IMEMR Language: En Journal: Avicenna J. Med. Biotechnol. Year: 2017